4Ohe Y. Chemoradiotherapy for lung cancer[ J]. Expert Opin Pharmacother,2005, 6: 2793-2804.
5Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J]. N Engl J Med, 2002, 346: 92-98.
6Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy[ J 1. J Clin Oncol, 2000, 18 : 2095-2103.
7Fossella FV, DeVore R, Kerr RN, et al. Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group [ J]. J Clin Oncol, 2000, 18: 2354-2362.
8Calvert H. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents [ J ]. Semin Oncol, 1999, 26: 3-10.
9Adjei AA. Pharmacology and mechanism of action of pemetrexed [J]. Clin Lung Cancer, 2004, 5(Suppl 2) : S51-55.
10Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small- cell lung cancer p~viously treated with chemotherapy [ J ]. J Clin Oncol, 2004, 22: 1589-1597.
